GLOBAL BRONCHITIS TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Global Bronchitis Treatment Market Size and Trends

Global bronchitis treatment market is estimated to be valued at USD 8.22 Bn in 2024 and is expected to reach USD 11.81 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 5.3% from 2024 to 2031.

To learn more about this report, Request sample copy

Global bronchitis treatment market is expected to witness steady growth over the forecast period, owing to  increasing respiratory diseases globally due to growing pollution levels and changing lifestyle. Heavy smoking is also widely accepted as one of the primary causative factors for both acute and chronic bronchitis. Rising pollution levels in urban areas have significantly contributed to the increase in respiratory ailments. Moreover, technology advancements have led to new product developments in recent years. Various drugs and devices are being introduced for effective treatment of bronchitis. However, lack of awareness regarding bronchitis in some developing nations  can hamper the market growth in the near future.

Market Driver – Growing Cases of Smoking-Induced Bronchitis

Global bronchitis treatment market growth is driven by rising number of cases of smoking-induced bronchitis. Tobacco smoking has been established as the primary cause of the two main types of bronchitis—acute bronchitis and chronic bronchitis. When a person smokes, the cilia or hair-like structures in the bronchial tubes get damaged due to the toxic chemicals in the smoke. This damage leads to reduced functioning of the cilia in clearing out mucus and foreign particles from the lungs. Thus, smokers are more prone to develop bronchitis, in which the bronchial tubes get inflamed and swollen. Chronic bronchitis has seen a rise in prevalence rates due to long-term smoking habits. The condition is marked by a cough that produces mucus most days of the month for at least three months of the year for two successive years. According to studies, around 9 out of 10 cases of chronic bronchitis can be attributed to cigarette smoking. With smokers accounting for over 1.1 billion individuals worldwide currently and the numbers estimated to rise further, there will be huge burden of smoking-related respiratory illnesses like chronic bronchitis, and this will boost demand for bronchodilators, cough suppressants, antibiotics and other bronchitis medications and therapies. Eefforts towards smoking cessation programs can also curb the impact of this driver.

To learn more about this report, Request sample copy

Increasing Air Pollution Worldwide

Increasing air pollution worldwide can drive the global bronchitis treatment market growth. As per World Health Organization (WHO), around 7 million people die every year due to air pollution exposure globally. Air pollution is one of the leading causes of chronic respiratory diseases like bronchitis, which damages the lungs over a long period of exposure to polluted air. Bronchitis causes inflammation in the bronchial tubes of lungs which leads to coughing, wheezing and shortness of breath.

Rising vehicular and industrial emission levels have tremendously deteriorated the air quality across major cities worldwide. According to the data from IQAir's 2021 World Air Quality Report, India had the highest annual average particulate matter (PM2.5) levels among the most polluted countries in the world. PM2.5 can easily enter deep into lungs and bloodstream, thus, increasing the risk of bronchitis and other lung diseases. China also witnessed sharp rise in air pollution levels post COVID lockdowns with most cities reporting unhealthy and hazardous air quality on daily basis. The growing population, urbanization and climate change has augmented the ground level ozone and other harmful pollutants concentration in the atmosphere. This surge in air pollution has led to exponential growth in bronchitis patient base worldwide. According to a study published by Global Asthma Network, Bangladesh witnessed over 50% increase in moderate to severe asthma cases among adults from 2010 to 2018, mostly attributed to air pollution. Rising disease incidence has boosted demand for bronchitis diagnostics, therapeutics and symptom management products globally. The market is witnessing increased adoption of combination therapies involving corticosteroids, antibiotics and bronchodilators.